Wedbush analyst David Nierengarten reiterates TScan Therapeutics (NASDAQ:TCRX) with a Outperform and maintains $10 price tar...

TScan Therapeutics announces pricing of an underwritten public offering of 2,472,581 shares of its voting common stock at a pub...

All shares of voting common stock and pre-funded warrants to be sold in the offering will be offered by TScan. The Company inte...

Over 40 solid tumor patients have completed all biomarker testing in the screening protocol; ~60% of these patients qualify for...

U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday.

Barclays analyst Peter Lawson maintains TScan Therapeutics (NASDAQ:TCRX) with a Overweight and raises the price target from ...

HC Wainwright & Co. analyst Andrew Fein reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $15 price t...